share_log

和鉑醫藥-B：翌日披露報表

HBM HOLDINGS-B: Next Day Disclosure Return

HKEX ·  Sep 11 19:39
Summary by Futu AI
和鉑醫藥控股有限公司（和铂医药-B）於2024年9月11日提交了翌日披露報表，披露其股份變動情況。根據報表，公司於2024年9月10日的已發行股份為768,845,410股，庫存股份為31,000股。在2024年9月11日，和鉑醫藥進行了股份購回活動，購回了100,000股普通股，每股購回價格為1.0897港元，購回後的庫存股份增至131,000股。該次購回股份將持作庫存股份，並非註銷。公司確認，此次股份購回活動已獲董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。購回後，公司的已發行股份總數為768,745,410股。此外，公司已確認在購回股份後的30天內，將不會進行任何新股發行或庫存股份再出售或轉讓。
和鉑醫藥控股有限公司（和铂医药-B）於2024年9月11日提交了翌日披露報表，披露其股份變動情況。根據報表，公司於2024年9月10日的已發行股份為768,845,410股，庫存股份為31,000股。在2024年9月11日，和鉑醫藥進行了股份購回活動，購回了100,000股普通股，每股購回價格為1.0897港元，購回後的庫存股份增至131,000股。該次購回股份將持作庫存股份，並非註銷。公司確認，此次股份購回活動已獲董事會正式授權批准，並遵守所有適用的上市規則、法律及其他監管規定。購回後，公司的已發行股份總數為768,745,410股。此外，公司已確認在購回股份後的30天內，將不會進行任何新股發行或庫存股份再出售或轉讓。
HepLink Pharmaceutical Holdings Limited (HepLink-B) submitted the next day disclosure report on September 11, 2024, disclosing its shareholding changes. According to the report, the company's issued shares on September 10, 2024 were 768,845,410 shares, with treasury shares of 31,000. On September 11, 2024, HepLink Pharmaceutical conducted a share repurchase activity, repurchasing 100,000 ordinary shares at a repurchase price of 1.0897 Hong Kong dollars per share, increasing the treasury shares to 131,000. The repurchased shares will be held as treasury shares, not canceled. The company confirmed that this share repurchase activity has been formally authorized and approved by the board of directors, and complies with all applicable listing rules, laws, and other regulatory requirements. After the repurchase, the total number of issued shares of the company is 768,745,410 shares. In addition, the company confirmed that within 30 days after the share repurchase, there will be no new share issuance or re-sale or transfer of treasury shares.
HepLink Pharmaceutical Holdings Limited (HepLink-B) submitted the next day disclosure report on September 11, 2024, disclosing its shareholding changes. According to the report, the company's issued shares on September 10, 2024 were 768,845,410 shares, with treasury shares of 31,000. On September 11, 2024, HepLink Pharmaceutical conducted a share repurchase activity, repurchasing 100,000 ordinary shares at a repurchase price of 1.0897 Hong Kong dollars per share, increasing the treasury shares to 131,000. The repurchased shares will be held as treasury shares, not canceled. The company confirmed that this share repurchase activity has been formally authorized and approved by the board of directors, and complies with all applicable listing rules, laws, and other regulatory requirements. After the repurchase, the total number of issued shares of the company is 768,745,410 shares. In addition, the company confirmed that within 30 days after the share repurchase, there will be no new share issuance or re-sale or transfer of treasury shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.